Physician Views: What scope for the next oral RA therapy?

Physician Views: What scope for the next oral RA therapy?

Code: FW-20150401 | Published: Apr-2015 | Pages: - | FirstWord
Price :

* Required Fields



The rheumatoid arthritis (RA) market is one of the largest in the pharmaceutical sector and is dominated by biologic therapies, primarily the TNF inhibitors. The three largest products in this category - AbbVies Humira, Johnson & Johnson and Merck & Co.s Remicade, and Amgen and Pfizers Enbrel - were positioned among the four biggest selling drug brands globally in 2014, generating combined sales of around $30 billion.

One of the key dynamics within this market is the emergence of biosimilar competition. Biosimilar versions of Remicade have already launched in Europe and are expected to debut in the US within in the next few years. How the availability of these products, and the pricing strategies attached to them, shape the broader market remains to be seen, but the value of the RA sector also continues to attract branded developers.

One such opportunity is focused on the continued development of small-molecule products that offer comparable efficacy and safety to the TNF inhibitors, but with the benefit of oral dosing. Pfizer has enjoyed a considerable first-to-market advantage here, having secured US approval for its Xeljanz franchise in 2012.

Xeljanz has largely failed to meet pre-launch revenue expectations, however, generating sales of $308 million in 2014, with this performance stemming partly from a delay to European approval. In addition, key opinion leaders (KOLs) interviewed by FirstWord for a new Therapy Trends report on the RAs market (for more details click HERE) also cite higher than expected pricing for Xeljanz as a notable barrier to usage.

With rebating flexibility in the US market already cited by analysts as a potential defensive strategy for the TNF inhibitor brands versus future biosimilar competition, it is perhaps not surprising that list pricing for Xeljanz almost on par with the TNF inhibitors has proven prohibitive in terms of uptake, particularly as many KOLs expected Pfizers drug to be priced lower.
What does the performance and positioning of Xeljanz mean for other oral JAK inhibitors in development, such as Eli Lillys baricitinib - for which Phase III data is expected imminently - or Galapagos Phase II-stage filgotinib, which is currently partnered with AbbVie?

Baricitinib, the most advanced competitor to Xeljanz, benefits from a once-daily dosing profile (versus twice-daily for Pfizers drug), but many KOLs expect pricing to play a key factor in driving uptake should Eli Lillys product reach the market

To better understand how the market for oral RA therapies is likely to evolve assuming that baricitinib, as expected, demonstrates Phase III data broadly comparable with Xeljanz, we are polling US-based rheumatologists with the following questions this week

- What is the most common reason for you not to prescribe Xeljanz in favour of a biologic RA therapy following methotrexate?
- Baricitinib (currently in Phase III studies) is expected to be the next oral RA drug to reach the market. Assuming efficacy, tolerability and side-effect profile are comparable to Xeljanz, how significant an advantage do you think once-daily dosing for baricitinib will be (versus current twice-daily dosing for Xeljanz)?
- Based on your experience in this market, what level of pricing discount versus Xeljanz do you think will be necessary to drive adoption of baricitinib in favour of Xeljanz?
- What impact do you think availability of a cheaper, once-daily oral treatment will have on overall uptake of oral RA therapies at the expense of biologic therapies?
- Do you think the availability of biosimilar anti-TNF products will have an impact in limiting the uptake of oral JAK inhibitors?

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]

2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal

3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at


There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare

Our Clients